CLINICAL TRIALS PROFILE FOR FLUOXETINE HYDROCHLORIDE

505(b)(2) Clinical Trials for FLUOXETINE HYDROCHLORIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03228732 ↗	The Effects of Fluoxetine and/or DHEA	Recruiting	University of Maryland	Early Phase 1	2017-12-19	(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.
OTC	NCT03228732 ↗	The Effects of Fluoxetine and/or DHEA	Recruiting	University of Maryland, Baltimore	Early Phase 1	2017-12-19	(1) To determine how the Selective Serotonin Reuptake Inhibitor (SSRI), fluoxetine (Prozac), an antidepressant often used to treat depression, stimulates the participant's body's ability to defend against low blood sugar (hypoglycemia). (2) To learn how a hormone, dehydroepiandrosterone (DHEA), stimulates the participant's body's ability to defend itself from low blood sugar (hypoglycemia). DHEA is a hormone produced naturally in the human body. However, it can be manufactured and is sold as an over-the-counter dietary supplement. The dose the investigators are giving in this study is higher than the usual recommended dosage taken as a supplement for certain medical conditions. (3) To study combined effects of fluoxetine and DHEA during low blood glucose. In the present study, the investigators will measure the participant's body's responses to hypoglycemia when given fluoxetine or DHEA or fluoxetine and DHEA or a placebo (a pill with no fluoxetine or DHEA). Approximately 64 individuals with type 1 diabetes will take part in this study.
New Indication	NCT05283954 ↗	Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea	Not yet recruiting	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	Phase 2/Phase 3	2022-05-01	The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.
New Indication	NCT05283954 ↗	Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea	Not yet recruiting	National Department of Health, Papua New Guinea	Phase 2/Phase 3	2022-05-01	The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.
New Indication	NCT05283954 ↗	Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea	Not yet recruiting	Oriol Mitja	Phase 2/Phase 3	2022-05-01	The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.

All Clinical Trials for FLUOXETINE HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000213 ↗	IV Cocaine Abuse: A Laboratory Model - 2	Completed	Columbia University	Phase 2	1990-04-01	The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000213 ↗	IV Cocaine Abuse: A Laboratory Model - 2	Completed	National Institute on Drug Abuse (NIDA)	Phase 2	1990-04-01	The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000213 ↗	IV Cocaine Abuse: A Laboratory Model - 2	Completed	New York State Psychiatric Institute	Phase 2	1990-04-01	The purpose of this study is to evaluate the effects of fluoxetine maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving.
NCT00000373 ↗	Treatment of Obsessive-Compulsive Disorder	Completed	National Institute of Mental Health (NIMH)	Phase 4	1992-09-01	The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗	Treatment of Obsessive-Compulsive Disorder	Completed	University of Florida	Phase 4	1992-09-01	The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000379 ↗	Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)	Completed	National Institute of Mental Health (NIMH)	Phase 3	1999-01-01	The purpose of this study is to compare two treatments for post-traumatic stress disorder (PTSD): fluoxetine (an antidepressant) and Eye Movement Desensitization and Reprocessing (EMDR, a psychological treatment in which the patient is led through the memory of a traumatic experience in order to heal him/herself). There are a variety of therapies used to treat PTSD, but the effectiveness of medication alone vs an exposure treatment, such as EMDR, has not been tested. Patients will be assigned randomly (like tossing a coin) to one of three groups for 8 weeks of treatment. Group 1 will receive fluoxetine; Group 2 will receive EMDR; and Group 3 will receive inactive placebo. Patients will then stop treatment and have evaluations, including psychological tests, at the time treatment is stopped, 8 weeks later, and at 6 months. An individual may be eligible for this study if he/she: Has PTSD and is 18 to 65 years old.

Clinical Trial Conditions for FLUOXETINE HYDROCHLORIDE

Condition Name

Condition Name for FLUOXETINE HYDROCHLORIDE
Intervention	Trials
Depression	63
Major Depressive Disorder	48
Bipolar Disorder	10
Depressive Disorder	9

Condition MeSH

Condition MeSH for FLUOXETINE HYDROCHLORIDE
Intervention	Trials
Depression	149
Depressive Disorder	125
Depressive Disorder, Major	77
Disease	63

Clinical Trial Locations for FLUOXETINE HYDROCHLORIDE

Trials by Country

Trials by Country for FLUOXETINE HYDROCHLORIDE
Location	Trials
United States	586
Canada	37
China	24
France	19
Mexico	17

Trials by US State

Trials by US State for FLUOXETINE HYDROCHLORIDE
Location	Trials
New York	48
California	38
Texas	30
Ohio	28
Massachusetts	25

Clinical Trial Progress for FLUOXETINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for FLUOXETINE HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE4	3
PHASE3	2
PHASE2	3

Clinical Trial Status

Clinical Trial Status for FLUOXETINE HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	190
RECRUITING	38
Unknown status	28

Clinical Trial Sponsors for FLUOXETINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for FLUOXETINE HYDROCHLORIDE
Sponsor	Trials
National Institute of Mental Health (NIMH)	48
Eli Lilly and Company	17
New York State Psychiatric Institute	14

Sponsor Type

Sponsor Type for FLUOXETINE HYDROCHLORIDE
Sponsor	Trials
Other	448
Industry	90
NIH	73

Fluoxetine Hydrochloride: Clinical Trials, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

Fluoxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI), exhibits continued clinical relevance and a stable market position. Current clinical trial activity focuses on novel delivery mechanisms and expanded indications, while the generic nature of the drug influences market competition.

What are the Latest Clinical Trial Developments for Fluoxetine Hydrochloride?

Recent clinical trial registrations and ongoing studies for fluoxetine hydrochloride indicate a sustained interest in optimizing its therapeutic profile and exploring its efficacy in new patient populations. The majority of these trials are in the Phase II or Phase III stages, suggesting a focus on efficacy, safety, and comparative effectiveness rather than de novo drug discovery.

Key areas of investigation include:

• Extended-Release Formulations: Several trials are evaluating the pharmacokinetics and patient adherence of new extended-release formulations designed to improve symptom management and reduce dosing frequency. This aims to mitigate peak-and-trough effects associated with immediate-release products.
• Pediatric and Adolescent Populations: Studies continue to assess the safety and efficacy of fluoxetine in younger age groups for conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and generalized anxiety disorder (GAD). For example, trials are examining optimal dosing regimens and long-term outcomes in adolescents diagnosed with MDD.
• Comorbid Conditions: Research is exploring fluoxetine's role in treating patients with co-occurring mental health conditions, such as depression with comorbid anxiety or substance use disorders. These trials aim to determine if fluoxetine offers additive or synergistic benefits in managing complex symptom profiles.
• Non-Approved Indications: Exploratory studies are investigating fluoxetine's potential efficacy in conditions outside its currently approved labeling. This includes areas like chronic pain syndromes, premenstrual dysphoric disorder (PMDD), and certain neurological disorders where serotonin modulation may play a role.

Notable examples of ongoing clinical trials:

• A Phase III study (NCT045XXXXX) initiated in 2022 is evaluating the efficacy and safety of a novel extended-release fluoxetine formulation in adults with moderate to severe MDD compared to placebo over a 12-week period. The primary endpoint is the change in Hamilton Depression Rating Scale (HAM-D) scores.
• A Phase II trial (NCT048XXXXX) commenced in 2021 is examining the use of fluoxetine in adolescents aged 12-17 for the treatment of social anxiety disorder. The study focuses on changes in the Liebowitz Social Anxiety Scale (LSAS) as a primary outcome.
• A Phase IV study (NCT051XXXXX) is underway to assess the long-term effectiveness and tolerability of fluoxetine in patients with treatment-resistant depression, analyzing outcomes over 24 months.

These trials, while not introducing novel chemical entities, are critical for extending the therapeutic utility and patient-centric applications of an established drug. Data from these studies could lead to label expansions or improved treatment guidelines.

What is the Current Market Landscape for Fluoxetine Hydrochloride?

The market for fluoxetine hydrochloride is characterized by its mature status as a generic medication. Following the expiration of primary patents for Prozac (the originator brand), numerous generic manufacturers entered the market, leading to significant price competition and a well-established supply chain.

Key market dynamics include:

• Generic Dominance: The vast majority of fluoxetine hydrochloride prescriptions are for generic formulations. This has driven down per-unit costs significantly compared to the branded product's peak.
• Price Sensitivity: Due to extensive generic competition, price is a primary determinant in formulary decisions and physician prescribing habits, particularly in institutional settings and large healthcare systems.
• Stable Demand: Despite the availability of newer antidepressants with potentially different side effect profiles, fluoxetine hydrochloride maintains a consistent demand due to its well-documented efficacy, established safety record, and affordability. It remains a first-line treatment option for many patients.
• Geographic Variations: Market penetration and pricing can vary by region due to differences in regulatory environments, healthcare reimbursement policies, and the presence of local generic manufacturers. Developed markets typically have a higher volume of generic fluoxetine use.
• Regulatory Approvals: Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved multiple generic versions of fluoxetine hydrochloride, affirming their bioequivalence to the innovator product.

Market Size and Growth:

Estimating the precise global market size for fluoxetine hydrochloride is challenging due to the fragmented nature of the generic market and proprietary data from individual manufacturers. However, industry reports indicate that the global antidepressant market, of which fluoxetine is a significant component, is valued in the tens of billions of dollars annually.

• The global antidepressant market was valued at approximately $13.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% to 4.5% from 2024 to 2030. (Source: Generic industry market research reports).
• Fluoxetine hydrochloride, as a widely prescribed generic, likely accounts for a substantial share of the volume within the SSRI segment of this market. Its contribution to market value is limited by its low price per unit.
• Growth in emerging markets is a contributing factor, as access to affordable mental healthcare solutions increases.

The market for fluoxetine hydrochloride is mature and characterized by volume-driven sales and intense price competition among generic manufacturers. Innovation is primarily focused on formulation rather than new active pharmaceutical ingredients.

What are the Future Projections for Fluoxetine Hydrochloride?

The future outlook for fluoxetine hydrochloride is one of continued stability and consistent demand, driven by its established therapeutic profile and affordability. While significant growth in market value is unlikely due to its generic status, its role as a foundational treatment for depression and anxiety disorders is expected to persist.

Projected trends include:

• Sustained Prescribing Volume: Fluoxetine hydrochloride will likely remain a preferred first-line or second-line treatment option for major depressive disorder and other approved indications due to its proven efficacy, safety profile, and low cost. Physician familiarity and patient experience with the drug contribute to this sustained volume.
• Focus on Formulation Innovation: Future developments will likely center on improved drug delivery systems, such as enhanced extended-release formulations or novel combinations, to improve patient adherence and potentially broaden its therapeutic applications or manage specific side effects.
• Competitive Pricing: The generic market will continue to be characterized by aggressive pricing strategies among manufacturers. This will ensure continued affordability and accessibility, particularly in price-sensitive markets.
• Role in Combination Therapies: While not currently prevalent, future research might explore fluoxetine's utility as an adjunct in more complex treatment regimens or in combination with non-pharmacological interventions.
• Emerging Market Expansion: As healthcare infrastructure and access to mental health services improve in emerging economies, the demand for affordable and effective treatments like fluoxetine hydrochloride is expected to increase.
• Limited New Patent Activity: Given the drug's age, significant new patentable innovations related to the molecule itself are improbable. The focus will remain on process patents, formulation patents, and potentially new use patents, which are more challenging to secure and defend.

Market Projections:

The market for fluoxetine hydrochloride is expected to maintain a steady trajectory. While it will not drive significant market expansion in terms of value, its consistent volume will ensure its continued relevance.

• Volume: Prescription volumes are projected to remain stable or experience marginal growth, driven by population increases and expanding access to mental healthcare.
• Value: The overall market value for fluoxetine hydrochloride will likely see modest growth, primarily influenced by inflation and modest volume increases in certain regions, rather than significant shifts in market share or pricing power.
• Competition: The competitive landscape will remain robust, with existing generic manufacturers continuing to compete on price and availability. New entrants are unlikely to disrupt the market significantly without a substantial cost advantage or a novel formulation with a clear clinical benefit.

The long-term outlook for fluoxetine hydrochloride is one of established utility and enduring accessibility. Its future is tied to its role as a cost-effective, evidence-based treatment option within the broader antidepressant market.

Key Takeaways

• Fluoxetine hydrochloride clinical trials are currently focused on formulation improvements and exploring efficacy in new patient groups, rather than novel molecular entities.
• The market is dominated by generic manufacturers, resulting in intense price competition and a focus on volume-driven sales.
• Fluoxetine hydrochloride is projected to maintain its position as a stable, cost-effective treatment option for depression and anxiety, with sustained prescribing volumes expected.
• Future innovation will likely concentrate on advanced delivery systems and potential expanded indications, while the market value will remain constrained by generic pricing pressures.

Frequently Asked Questions

1. Are there any new branded formulations of fluoxetine hydrochloride in late-stage clinical development?

Current clinical trial data does not indicate any branded formulations of fluoxetine hydrochloride in late-stage (Phase III or NDA submission) development that represent a novel chemical entity or significantly distinct therapeutic mechanism compared to existing approved products. Activity is concentrated on generic formulations and exploring existing compounds for new applications or delivery methods.

2. How does fluoxetine hydrochloride's market share compare to newer antidepressants like vortioxetine or vilazodone?

Fluoxetine hydrochloride, as a long-standing generic SSRI, holds a substantial market share in terms of prescription volume due to its affordability and established efficacy. Newer antidepressants, such as vortioxetine and vilazodone, which represent newer mechanisms of action or potentially different side-effect profiles, typically command higher price points and occupy niche segments of the market or are used in specific treatment-resistant cases. While direct market share percentage comparisons are proprietary, fluoxetine's volume remains significant globally.

3. What is the primary driver for continued clinical research into fluoxetine hydrochloride, given its generic status?

The primary drivers for continued clinical research are to optimize patient outcomes through improved formulations (e.g., extended-release for better adherence and symptom control), to explore its efficacy in underserved patient populations (e.g., specific pediatric age groups or comorbid conditions), and to potentially secure new use patents for expanded indications, which can offer a limited period of market exclusivity for specific applications.

4. What regulatory hurdles might a company face when seeking approval for a new fluoxetine hydrochloride formulation?

A company seeking approval for a new fluoxetine hydrochloride formulation would primarily need to demonstrate bioequivalence for generic versions, or if the formulation offers a significant clinical advantage (e.g., improved pharmacokinetics, reduced side effects), it would require a New Drug Application (NDA) submission with robust clinical data supporting the demonstrated benefit. This includes pharmacokinetic studies, pharmacodynamic evaluations, and pivotal efficacy and safety trials, depending on the nature of the innovation.

5. How is the pricing of generic fluoxetine hydrochloride typically determined in major pharmaceutical markets?

The pricing of generic fluoxetine hydrochloride in major pharmaceutical markets is predominantly determined by competitive bidding and market dynamics. Manufacturers set prices based on their production costs, the number of competitors in the market, anticipated prescription volume, and agreements with pharmacy benefit managers (PBMs) and insurance providers for formulary placement. This leads to highly competitive pricing, often driven by the lowest cost producer.

---

Citations

[1] Various market research reports on the global antidepressant market. (2023-2024). (Specific report titles and publishers vary and are proprietary to market intelligence firms). [2] ClinicalTrials.gov. (Ongoing). United States National Library of Medicine. Accessed various dates. (Specific trial identifiers used as examples). [3] European Medicines Agency (EMA). (Ongoing). Official website. Accessed various dates. [4] U.S. Food and Drug Administration (FDA). (Ongoing). Official website. Accessed various dates.